The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 18, 2022

Filed:

May. 14, 2018
Applicant:

Domain Therapeutics, Illkirch Graffenstaden, FR;

Inventors:

Anne-Laure Blayo, Souffelweyersheim, FR;

Thomas Catelain, Strasbourg, FR;

Ismet Dorange, Stockholm, SE;

Cédric Genet, Kientzheim, FR;

Baptiste Manteau, Ways, BE;

Stanislas Mayer, Eschau, FR;

Stephan Schann, Illkirch, FR;

Assignee:

Domain Therapeutics, Illkirch Graffenstaden, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/14 (2006.01); C07D 223/18 (2006.01); C07D 401/10 (2006.01); C07D 401/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 487/14 (2006.01); C07D 495/04 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C07D 471/14 (2013.01); C07D 223/18 (2013.01); C07D 401/10 (2013.01); C07D 401/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 487/14 (2013.01); C07D 495/04 (2013.01); G01N 33/6872 (2013.01);
Abstract

The present invention provides novel heterocyclic compounds of the general formula (I), including novel compounds of formula (Ia), and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) or (Ia) and the pharmaceutical compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. The compounds of formula (I) or (Ia) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. The present invention further provides compounds of formula (I) or (Ia) that are modulators of metabotropic glutamate receptors (mGluRs), particularly positive allosteric modulators of mGluRs, and more specifically positive allosteric modulators of mGluR3.


Find Patent Forward Citations

Loading…